

When health insurance is not enough.®

## **Financial Statements**

For the Year Ended December 31, 2016

and Report Thereon

Certified Public Accountants



#### INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of the HealthWell Foundation

We have audited the accompanying financial statements of the HealthWell Foundation (the Foundation), which comprise the statement of financial position as of December 31, 2016, and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements.

#### Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### **Auditor's Responsibility**

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### **Opinion**

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the HealthWell Foundation as of December 31, 2016, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Raffa, P.C.

Raffa, P.C.

Washington, DC June 21, 2017

## STATEMENT OF FINANCIAL POSITION December 31, 2016

\_\_\_\_\_

| ASSETS                                    |                |
|---|----------------|
| Cash and cash equivalents                 | \$ 29,003,342  |
| Investments                               | 77,495,177     |
| Interest receivable                       | 200,260        |
| Pledges receivable                        | 20,493,088     |
| Prepaid expenses                          | 56,241         |
| Deposit                                   | 8,218          |
| Property and equipment, net               | 334,431        |
| TOTAL ASSETS                              | \$ 127,590,757 |
| LIABILITIES AND NET ASSETS Liabilities    |                |
| Accounts payable and accrued expenses     | \$ 3,154,252   |
| Copayments and premium assistance payable | 4,319,829      |
| Deferred rent                             | 39,493         |
| Bolottod total                            |                |
| TOTAL LIABILITIES                         | 7,513,574      |
| Net Assets                                |                |
| Unrestricted                              | 355,026        |
| Temporarily restricted                    |                |
| Committed to patients                     | 57,878,248     |
| Uncommitted                               | 61,843,909     |
| Total Tanas and Destricted                | 440 700 457    |
| Total Temporarily Restricted              | 119,722,157    |
| TOTAL NET ASSETS                          | 120,077,183    |
| TOTAL LIABILITIES AND NET ASSETS          | \$ 127,590,757 |

# STATEMENT OF ACTIVITIES For the Year Ended December 31, 2016

\_\_\_\_

| DEVENUE AND OUDDODT  | Unrestricted      | Temporarily<br>Restricted | Total                     |
|--|-------------------|---------------------------|---------------------------|
| REVENUE AND SUPPORT  | ф 400 <b>7</b> 00 | ф. 400 CC4 0C0            | Ф 400 004 40 <del>7</del> |
| Contributions  | \$ 426,739        | \$ 138,664,368            | \$ 139,091,107            |
| Investment income, net                                     | 1,809,218         | -                         | 1,809,218                 |
| Net assets released from restrictions:                     | 107 007 600       | (407 007 600)             |                           |
| Satisfaction of program restrictions                       | 107,027,609       | (107,027,609)             | <del>-</del>              |
| TOTAL REVENUE AND SUPPORT                                  | 109,263,566       | 31,636,759                | 140,900,325               |
| EXPENSES   |                   |                           |                           |
| Program Services:  |                   |                           |                           |
| Multiple Sclerosis – Medicare Access                       | 38,387,298        | -                         | 38,387,298                |
| Hepatitis C  | 15,101,168        | _                         | 15,101,168                |
| Non-Small Cell Lung Cancer – Medicare Access               | 11,137,570        | -                         | 11,137,570                |
| Pulmonary Fibrosis   | 8,241,400         | -                         | 8,241,400                 |
| Cystic Fibrosis  | 7,390,083         | -                         | 7,390,083                 |
| Immunosuppressive Treatment for                            | , ,               |                           | , ,                       |
| Solid Organ Transplant Recipients – Medicare Access        | 4,188,239         | -                         | 4,188,239                 |
| Chronic Myeloid Leukemia – Medicare Access                 | 3,448,377         | _                         | 3,448,377                 |
| Systemic Lupus Erythematosus                               | 3,029,778         | _                         | 3,029,778                 |
| Carcinoid Tumors and Associated Symptoms – Medicare Access | 2,179,205         | _                         | 2,179,205                 |
| Urticaria  | 1,775,907         | _                         | 1,775,907                 |
| Multiple Myeloma – Medicare Access                         | 1,688,893         | _                         | 1,688,893                 |
| Breast Cancer – Medicare Access                            | 1,659,982         | _                         | 1,659,982                 |
| Cytomegalovirus Disease – Prevention and Treatment         | 1,352,517         | _                         | 1,352,517                 |
| Growth Hormone Deficiency                                  | 1,138,875         | _                         | 1,138,875                 |
| Melanoma   | 1,038,458         | _                         | 1,038,458                 |
| Renal Cell Carcinoma – Medicare Access                     | 902,878           | _                         | 902,878                   |
| Melanoma – Medicare Access                                 | 770,892           | _                         | 770,892                   |
| Gout   | 704,691           | -                         | 704,691                   |
| Dupuytren's Disease  | 696,466           | _                         | 696,466                   |
| Peyronie's Disease   | 579,638           | _                         | 579,638                   |
| Head and Neck Cancer – Medicare Access                     | 506,536           | _                         | 506,536                   |
| ANCA – Associated Vasculitis, Wegener's and                | 000,000           |                           | 000,000                   |
| Granulomatosis with Polyangiitis                           | 486,066           | _                         | 486,066                   |
| Pediatric Assistance                                       | 319,959           | _                         | 319,959                   |
| Secondary Hyperparathyroidism                              | 253,582           | _                         | 253,582                   |
| Diabetic Foot Ulcers                                       | 231,748           | _                         | 231,748                   |
| Asthma   | 199,761           | _                         | 199,761                   |
| Non-Small Cell Lung Cancer                                 | 151,706           | -                         | 151,706                   |
| Fungal Infections – Aspergillosis and Candidiasis          | 80,975            | _                         | 80,975                    |
| Porphyrias   | 28,246            | _                         | 28,246                    |
| Post-Menopausal Osteoporosis – Medicare Access             | 22,253            | _                         | 22,253                    |
| Other  | 20,334            | _                         | 20,334                    |
| Chemotherapy-Induced Neutropenia – Medicare Access         | 17,854            | _                         | 17,854                    |
| Bone Metastases – Medicare Access                          | 12,978            | _                         | 12,978                    |
| Inflammatory Bowel Disease – Medicare Access               | 412               | _                         | 412                       |
| Wilms' Tumor   | 342               | _                         | 342                       |
| Gout Travel Fund   | 275               | -<br>-                    | 275                       |
| Urea Cycle Disorders                                       | 75                | _                         | 75                        |
| Grod Gyold Bioordoro                                       |                   |                           |                           |
| Total Program Services                                     | 107,745,417       |                           | 107,745,417               |

## STATEMENT OF ACTIVITIES For the Year Ended December 31, 2016

(Continued)

|   | <u> </u> | nrestricted |    | nporarily<br>stricted | <br>Total       |
|---|----------|-------------|----|-----------------------|-----------------|
| EXPENSES (CONTINUED) Supporting Services: |          |             |    |                       |                 |
| Management and general                    | \$       | 1,014,154   | \$ | -                     | \$<br>1,014,154 |
| Marketing and communications              |          | 545,793     |    | -                     | 545,793         |
| Fundraising                               |          | 534,678     |    |                       | <br>534,678     |
| Total Supporting Services                 |          | 2,094,625   |    |                       | <br>2,094,625   |
| TOTAL EXPENSES                            |          | 109,840,042 |    |                       | <br>109,840,042 |
| CHANGE IN NET ASSETS                      |          | (576,476)   | 3  | 1,636,759             | 31,060,283      |
| NET ASSETS, BEGINNING OF YEAR             |          | 931,502     | 8  | 8,085,398             | 89,016,900      |
|   |          |             |    |                       |                 |

NET ASSETS, END OF YEAR

**\$** 355,026 **\$** 119,722,157 **\$** 120,077,183

## STATEMENT OF FUNCTIONAL EXPENSES For the Year Ended December 31, 2016

\_\_\_\_

Supporting Services

|                                   | Program<br>Services | Management<br>and General | Education and<br>Outreach | Fundraising | Total<br>Supporting<br>Services | Total          |
|-----------------------------------|---------------------|---------------------------|---------------------------|-------------|---------------------------------|----------------|
| Patient grants                    | \$ 102,016,067      | \$ -                      | \$ -                      | \$ -        | \$ -                            | \$ 102,016,067 |
| Contracted services               | 4,280,178           | 124,076                   | 131,715                   | -           | 255,791                         | 4,535,969      |
| Salaries and wages                | 401,485             | 394,319                   | 253,846                   | 228,455     | 876,620                         | 1,278,105      |
| Professional fees                 | 333,159             | 140,585                   | -                         | -           | 140,585                         | 473,744        |
| Fringe benefits and payroll taxes | 101,664             | 117,745                   | 72,500                    | 35,367      | 225,612                         | 327,276        |
| Telecommunications and systems    | 313,325             | 3,709                     | -                         | -           | 3,709                           | 317,034        |
| Marketing                         | -                   | -                         | 44,729                    | 206,189     | 250,918                         | 250,918        |
| Depreciation and amortization     | 78,933              | 30,785                    | -                         | -           | 30,785                          | 109,718        |
| Occupancy                         | 35,103              | 31,907                    | 20,486                    | 10,558      | 62,951                          | 98,054         |
| Software licenses                 | 82,959              | 5,650                     | -                         | -           | 5,650                           | 88,609         |
| Board honoraria                   | -                   | 77,888                    | -                         | -           | 77,888                          | 77,888         |
| Miscellaneous                     | 6,183               | 12,547                    | 5,953                     | 35,165      | 53,665                          | 59,848         |
| Printing and postage              | 43,742              | 7,798                     | -                         | -           | 7,798                           | 51,540         |
| Bank charges                      | 38,171              | 1,004                     | -                         | 4,010       | 5,014                           | 43,185         |
| Interest                          | -                   | 38,500                    | -                         | -           | 38,500                          | 38,500         |
| Travel and meals                  | -                   | 17,412                    | 14,765                    | -           | 32,177                          | 32,177         |
| Supplies                          | 12,864              | 1,629                     | 1,068                     | 626         | 3,323                           | 16,187         |
| State registration fees           | -                   | -                         | -                         | 13,897      | 13,897                          | 13,897         |
| Insurance                         | 1,584               | 8,600                     | 731                       | 411         | 9,742                           | 11,326         |
| TOTAL EXPENSES                    | \$ 107,745,417      | \$ 1,014,154              | \$ 545,793                | \$ 534,678  | \$ 2,094,625                    | \$ 109,840,042 |

#### STATEMENT OF CASH FLOWS

## For the Year Ended December 31, 2016 Increase (Decrease) in Cash and Cash Equivalents

| CASH FLOWS FROM OPERATING ACTIVITIES                      |                  |
|---|------------------|
| Change in net assets                                      | \$<br>31,060,283 |
| Adjustments to reconcile change in net assets to net cash |                  |
| provided by operating activities:                         |                  |
| Depreciation and amortization                             | 109,718          |
| Net realized and unrealized losses on investments         | (200,558)        |
| Changes in assets and liabilities:                        |                  |
| Interest receivable                                       | (118,661)        |
| Pledges receivable  | (5,693,088)      |
| Prepaid expenses  | (14,936)         |
| Deposit   | 8,219            |
| Accounts payable and accrued expenses                     | 1,406,959        |
| Copayments and premium assistance payable                 | 2,011,371        |
| Deferred rent   | <br>39,493       |
|   |                  |
| NET CASH PROVIDED BY OPERATING ACTIVITIES                 | <br>28,608,800   |
| CASH FLOWS FROM INVESTING ACTIVITIES                      |                  |
| Purchases of property and equipment                       | (170,093)        |
| Proceeds from sales and maturities of investments         | 8,000,000        |
| Purchases of investments                                  | (14,486,170)     |
|   |                  |
| NET CASH USED IN INVESTING ACTIVITIES                     | <br>(6,656,263)  |
| CASH FLOWS FROM FINANCING ACTIVITIES                      |                  |
| Payments made to portfolio loan                           | (13,000,000)     |
| Proceeds from portfolio loan                              | 13,000,000       |
|   | <u> </u>         |
| NET CASH USED IN FINANCING ACTIVITIES                     | <br>-            |
| NET INCREASE IN CASH AND CASH EQUIVALENTS                 | 21,952,537       |
|   |                  |
| CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR              | <br>7,050,805    |
| CASH AND CASH EQUIVALENTS, END OF YEAR                    | \$<br>29,003,342 |
|   |                  |

## NOTES TO FINANCIAL STATEMENTS For the Year Ended December 31, 2016

\_\_\_\_\_

## 1. Organization and Nature of Activities

### **Organization**

The HealthWell Foundation (the Foundation) is an independent, nonprofit organization that provides financial assistance to underinsured adults and children living with chronic or life-altering diseases, such as cancer, asthma and autoimmune disorders. The Foundation helps eligible individuals afford out-of-pocket costs for prescription drug copayments, coinsurance, deductibles, premiums and other select out-of-pocket costs. The Foundation's primary source of revenue is contributions from corporations and individuals.

## 2. Summary of Significant Accounting Policies

#### **Basis of Accounting**

The Foundation's financial statements have been prepared on the accrual basis of accounting. Accordingly, revenue is recognized when earned and expenses are recorded as the obligations are incurred.

#### **Cash and Cash Equivalents**

For financial statement reporting purposes, cash and cash equivalents include demand deposits and money market funds, excluding money market funds held in investment accounts.

#### **Investments**

Investments consist of exchange-traded funds, corporate bonds, government securities, money market funds, mutual funds, municipal bonds and certificates of deposit. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Realized gains and losses are recognized upon the sale or disposal of the investment. Interest and dividend income is recorded as earned. Unrealized gains and losses due to market fluctuations during the year are recognized as unrestricted revenue and support in the accompanying statement of activities.

### **Property and Equipment**

Property and equipment are recorded at cost and are depreciated or amortized using the straight-line method over the estimated useful lives of the assets, which are five years. It is the Foundation's policy to capitalize purchases of property and equipment that cost \$5,000 or more. Expenditures for major repairs and improvements are capitalized; expenditures for minor repairs and maintenance are expensed as incurred. Upon the disposal of an asset, the appropriate property accounts are reduced by the related costs and accumulated depreciation or amortization. The resulting gains or losses are reflected in the accompanying statement of activities.

## NOTES TO FINANCIAL STATEMENTS For the Year Ended December 31, 2016

\_\_\_\_

2. Summary of Significant Accounting Policies (continued)

### **Net Assets**

The Foundation's net assets are classified based on the existence or absence of donor-imposed restrictions. Accordingly, the Foundation's net assets are classified and reported as follows:

- Unrestricted net assets Net assets not subject to any donor-imposed stipulations or other legal limitations.
- Temporarily restricted net assets Net assets subject to donor-imposed stipulations that may be met by the Foundation's actions and/or the passage of time. Grants awarded to patients that have not yet been expended by the patients are reported as temporarily restricted net assets committed to patients.

#### **Fair Value Measurement**

Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 820, Fair Value Measurement defines fair value and establishes a framework for measuring fair value for assets and liabilities that are measured at fair value on a recurring basis. In accordance with the accounting standards for fair value measurements for those assets and liabilities that are measured at fair value on a recurring basis, the Foundation has categorized its applicable financial instruments into a required fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure the financial instruments fall within different levels of the fair value hierarchy, the categorization is based on the lowest-level input that is significant to the fair value measurement of the instrument. Applicable financial assets and liabilities are categorized based on the inputs to the valuation techniques as follows:

Level 1 – Inputs based on quoted prices (unadjusted) in active markets for identical assets or liabilities accessible at the measurement date.

Level 2 – Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets.

Level 3 – Unobservable inputs for the asset or liability, including the reporting entity's own assumptions in determining the fair value measurement.

As of and for the year ended December 31, 2016, only the Foundation's investments, as described in Notes 3 and 8, were measured at fair value on a recurring basis.

## NOTES TO FINANCIAL STATEMENTS For the Year Ended December 31, 2016

\_\_\_\_

2. Summary of Significant Accounting Policies (continued)

#### **Revenue Recognition**

In accordance with FASB ASC Topic *Not-for-Profit Organizations*, contributions received are recorded as unrestricted, temporarily restricted, or permanently restricted revenue and support depending on the existence and/or nature of any donor restrictions. Donor-restricted revenue is reported as an increase in temporarily restricted net assets, depending on the nature of the restriction. When a donor restriction expires (that is, when a stipulated time restriction ends or purpose restriction is accomplished), temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities as net assets released from restrictions.

#### **Program Services**

The Foundation awards financial assistance to underinsured patients living with chronic or lifealtering diseases. The Foundation records this financial assistance as program service expense when the services are provided, rather than when the assistance is awarded, as payments are contingent upon the patients obtaining the approved medications and/or services.

The Foundation has instituted a process for withdrawing and adjusting the original patient assistance committed to, but not subsequently used by, the patient so that the funds are available for new awards. Funds awarded to patients that have not yet been expended by the patients are recorded as temporarily restricted net assets committed to patients on the accompanying statement of financial position.

### **Copayments and Premium Assistance Payable**

An estimated liability for unpaid copayments and premium claims incurred, but not reported, as of year-end, based upon actual subsequent claims payments, is recorded in the accompanying statement of financial position.

#### **Functional Allocation of Expenses**

The costs of providing the various programs and activities have been summarized on a functional basis in the accompanying statement of functional expenses. Expenses that are not directly charged to a program or supporting service are allocated among the programs and supporting services based on patient grant expenses.

### **Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

## NOTES TO FINANCIAL STATEMENTS For the Year Ended December 31, 2016

#### 3. Investments

The Foundation's investments as of December 31, 2016, are summarized as follows:

| Exchange-traded funds – closed-end funds | \$22,169,744       |
|--|--------------------|
| Mutual funds                             | 7,120,898          |
| Money market funds                       | 10,506,945         |
| Certificates of deposit                  | 203,280            |
| Corporate bonds                          | 21,779,592         |
| Municipal bonds                          | 586,264            |
| Government securities                    | <u> 15,128,454</u> |
| Total Investments                        | \$77,495,177       |

Investment income, including interest earned on cash and cash equivalents, was as follows for the year ended December 31, 2016:

| Interest and dividends | \$ 1,866,191        |
|------------------------|---------------------|
| Realized gains         | 266,048             |
| Unrealized losses      | (65,490)            |
| Investment fees        | (257,531)           |
| Investment Income, Net | <u>\$ 1,809,218</u> |

#### 4. Pledges Receivable

Pledges receivable represent grants and contributions from corporations that are due within one year. Pledges receivable are deemed to be fully collectible. Approximately 89% of pledges receivable were due from three contributors as of December 31, 2016.

## 5. Property and Equipment

Property and equipment consisted of the following at December 31, 2016:

| Computer software                               | \$ 1,170,403      |
|---|-------------------|
| Computer equipment                              | 137,470           |
| Furniture                                       | <u>116,858</u>    |
| Total Property and Equipment                    | 1,424,731         |
| Less: Accumulated Depreciation and Amortization | (1,090,300)       |
| Property and Equipment, Net                     | <u>\$ 334,431</u> |

Depreciation and amortization expense totaled \$109,718 for the year ended December 31, 2016.

## NOTES TO FINANCIAL STATEMENTS For the Year Ended December 31, 2016

## 6. Temporarily Restricted Net Assets

As of December 31, 2016, temporarily restricted net assets were available for the following disease funds:

| Multiple Sclerosis – Medicare Access                       | \$11,587,955 |
|--|--------------|
| Hepatitis C  | 21,853,279   |
| Pulmonary Fibrosis   | 21,770,230   |
| Multiple Myeloma – Medicare Access                         | 14,557,977   |
| Non-Small Cell Lung Cancer – Medicare Access               | 10,877,474   |
| Cystic Fibrosis  | 8,868,427    |
| Secondary Hyperparathyroidism                              | 6,245,318    |
| Systemic Lupus Erythematosus                               | 2,999,482    |
| Urticaria  | 2,761,468    |
| Bone Metastases – Medicare Access                          | 2,733,378    |
| Chemotherapy-Induced Neutropenia – Medicare Access         | 2,416,276    |
| Breast Cancer  | 2,378,097    |
| Gout – Medicare Access                                     | 1,565,416    |
| Carcinoid Tumors and Associated Symptoms – Medicare Access | 1,457,331    |
| Chronic Myeloid Leukemia – Medicare Access                 | 1,136,638    |
| Inflammatory Bowel Disease – Medicare Access               | 823,372      |
| Melanoma – Medicare Access                                 | 833,142      |
| Peyronie's Disease   | 712,890      |
| Melanoma   | 620,731      |
| Dupuytren's Disease  | 562,436      |
| Cytomegalovirus Disease                                    | 549,155      |
| Non-Small Cell Lung Cancer                                 | 518,031      |
| Head and Neck Cancer                                       | 466,106      |
| ANCA – Associated Vasculitis, Wegener's                    |              |
| and Granulomatosis with Polyangiitis                       | 408,596      |
| Fungal Infections-Aspergillosis and Candidiasis            | 169,025      |
| Growth Hormone Deficiency                                  | 158,224      |
| Diabetic Foot Ulcers                                       | 118,252      |
| Iron Overload as a Result of Blood Transfusions            | 102,766      |
| Autoimmune – Medicare Access                               | 97,124       |
| Emergency Cancer Relief                                    | 87,484       |
| Porphyrias   | 51,101       |
| Urea Cycle Disorders                                       | 44,863       |
| Carcinoid Tumors and Associated Symptoms                   | 41,604       |
| Gout Travel Fund   | 24,725       |
| Colorectal Carcinoma                                       | 24,253       |
| Anemia Associated with Chronic Renal Insufficiency/Failure | 22,675       |
| Crohn's Disease – Medicare Access                          | 20,638       |
| Post-Menopausal Osteoporosis – Medicare Access             | 15,550       |
| Wilms' Tumor   | 14,401       |
| Ankylosing Spondylitis                                     | 12,923       |

## NOTES TO FINANCIAL STATEMENTS For the Year Ended December 31, 2016

\_\_\_\_

## 6. Temporarily Restricted Net Assets (continued)

| Psoriasis                           | \$     | 3,869   |
|-------------------------------------|--------|---------|
| Idiopathic Thrombocytopenic Purpura |        | 3,721   |
| Non-Hodgkin's Lymphoma              |        | 2,140   |
| Rheumatoid Arthritis                |        | 1,882   |
| Macular Degeneration                |        | 1,379   |
| Psoriatic Arthritis                 |        | 353     |
| Total                               | \$119. | 722,157 |

#### 7. Pension Plan

The Foundation maintains a defined-contribution plan under Section 401(k) of the Internal Revenue Code (the IRC). Under the 401(k) plan, participants may elect to contribute annually to the plan amounts up to the federal tax limit, which was \$18,000 for 2016. The Foundation matches 100% of an employee's contributions, up to 6% of the employee's salary. Employees are vested in their own contributions and employer matching contributions at the time the contributions are made. The Foundation's pension expense totaled \$62,722 for the year ended December 31, 2016.

#### 8. Fair Value Measurement

The following table summarizes the Foundation's assets measured at fair value on a recurring basis as of December 31, 2016:

|                                | Fair Value   | Quoted Prices<br>in Active<br>Markets for<br>Identical<br>Assets<br>(Level 1) | Significant<br>Other<br>Observable<br>Inputs<br>(Level 2) | Unobs<br>In | nificant<br>ervable<br>puts<br>vel 3) |
|--------------------------------|--------------|---|---|-------------|---------------------------------------|
| Exchange-traded funds          |              |   |   |             | <del> ,</del>                         |
| Closed-end funds:              |              |   |   |             |                                       |
| Equity allocation Taxable bond | \$20,176,455 | \$ 20,176,455   | \$ -  | \$          | -                                     |
| allocation                     | 1,993,289    | 1,993,289   |   |             |                                       |
| Total Exchange-                |              |   |   |             |                                       |
| Traded Funds                   | 22,169,744   | <u>22,169,744</u>   |   |             |                                       |

## NOTES TO FINANCIAL STATEMENTS For the Year Ended December 31, 2016

\_\_\_\_

## 8. Fair Value Measurement (continued)

|                         |                     | Quoted Prices       |                     |              |
|-------------------------|---------------------|---------------------|---------------------|--------------|
|                         |                     | in Active           | Significant         |              |
|                         |                     | Markets for         | Other               | Significant  |
|                         |                     | Identical           | Observable          | Unobservable |
|                         |                     | Assets              | Inputs              | Inputs       |
| (Continued)             | Fair Value          | (Level 1)           | (Level 2)           | (Level 3)    |
| Mutual funds:           |                     |                     |                     |              |
| Nontraditional bond     |                     |                     |                     |              |
| funds                   | \$ 2,846,895        | \$ 2,846,895        | \$ -                | \$ -         |
| Allocation funds        | 2,263,107           | 2,263,107           | -                   | -            |
| Market neutral          | 2,010,896           | 2,010,896           |                     |              |
| Total Mutual            |                     |                     |                     |              |
| Funds                   | <u>7,120,898</u>    | 7,120,898           |                     |              |
| Money market funds      | 10,506,945          | 10,506,945          | -                   | -            |
| Certificates of deposit | 203,280             | -                   | 203,280             | -            |
| Government securities   | 15,128,454          | -                   | 15,128,454          | -            |
| Municipal bonds         | 586,264             | -                   | 586,264             | -            |
| Corporate bonds         | 21,779,592          |                     | 21,779,592          |              |
| Total Assets            | <u>\$77,495,177</u> | <u>\$39,797,587</u> | <u>\$37,697,590</u> | <u>\$ -</u>  |

As of December 31, 2016, the Foundation used the following methods and significant assumptions to estimate fair value for assets recorded at fair value:

Money market funds; exchange-traded funds – closed-end; – Where quoted prices are available in an active market, securities are classified within Level 1 of the valuation hierarchy. Level 1 securities include common stock and money market funds.

*Mutual funds* – Valued at the quoted market price of the fund, which represents the net asset value of the share held by the fund at year-end.

Certificates of deposit – Certificates of deposit have original maturity dates in excess of 90 days. A yield-based matrix system was used to arrive at an estimated market value for these instruments which are classified within Level 2 of the valuation hierarchy.

Corporate bonds – Valued at fair value by discounting the related cash flows based on current yields of similar instruments with comparable characteristics, as provided by a third party using a computerized valuation formula. If quoted market prices are not available, then fair values are estimated using the most recent bid prices in the over-the-counter market in which the individual securities are traded and adjusted for other factors, such as interest rates, credit, etc., as determined by the broker and/or custodian.

Government securities and municipal bonds – Represent securities that are generally not traded on a daily basis. The fair value estimates of such investments are based on observable market information, rather than market quotes. Accordingly, the estimates of fair value for such investments, as provided by the pricing service, are included in Level 2.

## NOTES TO FINANCIAL STATEMENTS For the Year Ended December 31, 2016

\_\_\_\_

### 9. Portfolio Loan Payable

The Foundation has a portfolio loan facility with a maximum limit of \$30,013,000 as of December 31, 2016, with interest rate tiers based on the amount of the portfolio loan. The limit is determined by the overall size and composition of the portfolio and varies accordingly. As of December 31, 2016, no amount was outstanding on the portfolio loan, and the facility carried an interest rate of 2.52%. Interest in specific investments totaling \$77,495,177 as of December 31, 2016, was held as collateral to secure the balance of the portfolio loan. For the year ended December 31, 2016, the Foundation incurred interest and other charges on the portfolio loan of \$38,500.

#### 10. Risks and Commitments

#### Cash

The Foundation maintains its cash with certain commercial financial institutions, which aggregate balances may exceed, at times, the Federal Deposit Insurance Corporation (FDIC) insured limit of \$250,000 per depositor per institution. As of December 31, 2016, the Foundation had approximately \$29,300,000 million in demand deposits which exceeded the maximum limit insured by the FDIC.

#### **Concentration of Revenue Risk**

During the year ended December 31, 2016, the Foundation received approximately 85% of its total revenue and support from five donors.

### **Operating Lease**

The Foundation leased commercial office space and certain equipment under an agreement with Covance Market Access (CMA) which expired in August 2015 and continued on a month-to-month basis through January 2016. The Foundation also had a services agreement with CMA, which included hotline support, which expired in January 2016. The lease and services agreement included an annual 3% increase. Expenses under the services agreement totaled approximately \$2,700,000 for the year ended December 31, 2016.

In September 2015, the Foundation signed a new operating lease for office space commencing February 2016 and continuing through June 30, 2021. Monthly base rent began at \$8,218, plus a prorated share of basic property operating costs. The Foundation paid a rental deposit equivalent to one month's base rent of \$8,218. The lease also contains a fixed

## NOTES TO FINANCIAL STATEMENTS For the Year Ended December 31, 2016

\_\_\_\_\_

### 10. Risks and Commitments (continued)

#### **Operating Lease (continued)**

escalation clause for increases in the annual minimum rent at a rate of 2.7% per year and there is a rent abatement for the first 180 days of the operating lease. Under GAAP, all rental payments, including rent increases, are recognized on a straight-line basis over the term of the lease.

The following is a schedule of future minimum lease payments as of December 31, 2016:

| For the Year Ending  December 31, |                   |
|-----------------------------------|-------------------|
| 2017                              | \$ 101,352        |
| 2018                              | 104,127           |
| 2019                              | 106,988           |
| 2020                              | 109,936           |
| 2021                              | <u>56,485</u>     |
| Total                             | <u>\$ 478.888</u> |

### **Patient Commitments**

At December 31, 2016, the Foundation had outstanding commitments to patients totaling \$57,878,248. These commitments are based upon amounts awarded by the Foundation for, but not yet expended on, copayments and premium assistance claims of patients as of December 31, 2016. As patients submit claims for approved medication and services, amounts committed to patients are transferred to copayments and premium assistance payable in the accompanying statement of financial position until the obligation is paid.

#### 11. Income Tax Status

The Foundation is exempt from federal income taxation, except for unrelated business income, under Section 501(c)(3) of the IRC and is classified by the Internal Revenue Service as other than a private foundation. No provision for income taxes was required for the year ended December 31, 2016, as the Foundation had no taxable unrelated business income.

The Foundation follows the authoritative guidance relating to accounting for uncertainty in income taxes included in FASB ASC Topic 740, *Income Taxes*. These provisions provide consistent guidance for the accounting for uncertainty in income taxes recognized in an entity's financial statements and prescribe a threshold of "more likely than not" for recognition and derecognition of tax positions taken or expected to be taken in a tax return. The Foundation performed an evaluation of uncertain tax positions for the year ended December 31, 2016, and determined that there were no matters that would require recognition in the financial statements or that may have any effect on its tax-exempt status. As of December 31, 2016, the statute of limitations for tax years 2013 through 2015 remains open

## NOTES TO FINANCIAL STATEMENTS For the Year Ended December 31, 2016

## 11. Income Tax Status (continued)

with the U.S. federal jurisdiction or the various states and local jurisdictions in which the Foundation files tax returns. It is the Foundation's policy to recognize interest and/or penalties related to uncertain tax positions, if any, in income tax expense. As of December 31, 2016, the Foundation had no accrual for interest and/or penalties.

## 12. Subsequent Events

In preparing the financial statements, the Foundation has evaluated events and transactions for potential recognition or disclosure through June 21, 2017, the date the financial statements were available to be issued. There were no subsequent events that require recognition or disclosure in these financial statements.